By Dr. H. Jack West One ongoing controversy in the world of managing cancer, especially one in which cures are elusive, is how high the bar should be to guide treatment recommendations. The “gold standard” to change treatment is a significant improvement in the primary endpoint, ideally overall survival, in a prospective, randomized phase III trial with several hundred or even several thousand people. In some settings, treatment recommendations may not even change until a few randomized phase III trials show the same significant improvement with a new treatment approach. But the reality is that sometimes we want… Read More
- #LCSM Chat Topic 12/03/2020: 2020–Wild Year for #LungCancer
- #LCSM Chat Topic 11/05/2020: Celebrating Safely During #COVID-19 Pandemic
- #LCSM Chat Topic 10/01/2020: Crazy year, crazy progress–#lungcancer at #ESMO20
- #LCSM Chat Topic 9/3/2020: Is #Cancer Advocacy for Everyone?
- #LCSM Chat Topic 8/6/2020: Update on #COVID19 and #LungCancer
#LCAM14 ALK biomarker cancer treatment plans clinical research clinical trials COVID-19; antigen test Drugs EGFR epatients immunotherapy LDCT lung cancer lung cancer awareness month lung cancer risk factors lung cancer screening Medicare coverage of LDCT over-treatment patient advocates PCORI Screening self-advocacy shared decision making trials World Cancer Day